Expertise in
3
conditions

Shozo Ohsumi

Matsuyama, JP 
Expertise in
3
conditions
Matsuyama, JP 

Overview

Shozo Ohsumi practices practicing medicine in Matsuyama, Japan.

Mr. Ohsumi is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Breast Cancer, BRCA Positive Breast Cancer, Ovarian Cancer, Mastectomy, and Salpingo-Oophorectomy.

He is actively involved in clinical research, co-authoring 137 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Matsuyama, Japan
Other Locations
7910280, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: July 23, 2026
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2023
Intervention Type: Radiation
Study Phase: Not Applicable
View 1 Less Clinical Trial

137 Total Publications

High-risk pathogenic germline variants in blood relatives of BRCA1/2 negative probands.
High-risk pathogenic germline variants in blood relatives of BRCA1/2 negative probands.
Journal: Breast cancer (Tokyo, Japan)
Published: December 26, 2023

Frequently Asked Questions about Shozo Ohsumi

Is Shozo Ohsumi a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Shozo Ohsumi is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Shozo Ohsumi participate in research or clinical trials?

Yes. Shozo Ohsumi has published 137 articles and abstracts on conditions like Breast Cancer. You can view a list of Shozo Ohsumi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Ohsumi's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile